<?xml version="1.0" encoding="UTF-8"?><urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url><loc>https://vigi-eye.com/analysis/2026-11-19-tablo-power-cord-overheating-alert-shows-how-a-simple-instruction-change-becomes</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19</news:publication_date><news:title>Tablo power cord overheating alert shows how a simple instruction change becomes a PV control</news:title></news:news></url><url><loc>https://vigi-eye.com/analysis/2026-11-19-lantern-pharma-s-first-tnbc-site-and-taiwan-start-meet-a-ceo-exit-and-a-4-0m-rai</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19</news:publication_date><news:title>Lantern Pharma&#x27;s first TNBC site and Taiwan start meet a CEO exit and a $4.0M raise</news:title></news:news></url><url><loc>https://vigi-eye.com/analysis/2026-11-19-eea-decision-191-2026-extends-six-eu-feed-additive-acts-to-eea-efta-markets-minu</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19</news:publication_date><news:title>EEA Decision 191/2026 extends six EU feed additive acts to EEA EFTA markets, minus Liechtenstein</news:title></news:news></url><url><loc>https://vigi-eye.com/analysis/2026-11-19-prescriber-fraud-plea-and-a-week-of-enforcement-signals-what-qa-and-compliance-s</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19</news:publication_date><news:title>Prescriber fraud plea and a week of enforcement signals: what QA and compliance should take from it</news:title></news:news></url><url><loc>https://vigi-eye.com/analysis/2026-11-19-fda-clears-infilbray-first-therapy-for-neurological-symptoms-of-type-3-gaucher-d</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19</news:publication_date><news:title>FDA clears Infilbray, first therapy for neurological symptoms of Type 3 Gaucher disease</news:title></news:news></url><url><loc>https://vigi-eye.com/analysis/2026-11-19-ema-s-new-eurd-list-what-pv-teams-should-check-before-the-next-psur-cycle</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19</news:publication_date><news:title>EMA&#x27;s new EURD list: what PV teams should check before the next PSUR cycle</news:title></news:news></url><url><loc>https://vigi-eye.com/analysis/2026-11-18-view-your-fda-approval-package-is-now-a-global-filing-asset-plan-it-like-one</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>Your FDA approval package is now a global filing asset. Plan it like one</news:title></news:news></url><url><loc>https://vigi-eye.com/analysis/2026-11-18-fda-s-lembaz-approval-sets-a-survival-benchmark-in-infantile-onset-niemann-pick</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>FDA&#x27;s Lembaz approval sets a survival benchmark in infantile-onset Niemann-Pick type C</news:title></news:news></url><url><loc>https://vigi-eye.com/analysis/2026-11-18-medicare-aco-savings-data-what-a-pv-team-can-and-cannot-take-from-cms-s-2025-res</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>Medicare ACO savings data: what a PV team can and cannot take from CMS&#x27;s 2025 results</news:title></news:news></url><url><loc>https://vigi-eye.com/analysis/2026-11-18-cms-releases-2027-medicare-cost-sharing-parameters-what-pricing-teams-should-che</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>CMS releases 2027 Medicare cost-sharing parameters: what pricing teams should check first</news:title></news:news></url><url><loc>https://vigi-eye.com/analysis/2026-11-18-uk-and-german-device-safety-notices-what-qa-can-and-can-t-learn-from-the-public</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>UK and German device safety notices: what QA can and can&#x27;t learn from the public lists</news:title></news:news></url><url><loc>https://vigi-eye.com/analysis/2026-11-18-fda-s-global-reliance-disclosure-program-what-minimally-redacted-approval-packag</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>FDA&#x27;s Global Reliance Disclosure Program: what minimally redacted approval packages mean for filings</news:title></news:news></url><url><loc>https://vigi-eye.com/analysis/2026-11-18-class-i-on-presource-kits-shows-how-an-infusion-set-recall-travels-into-convenie</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>Class I on Presource kits shows how an infusion-set recall travels into convenience packs</news:title></news:news></url><url><loc>https://vigi-eye.com/analysis/2026-11-17-cyion-s-528-336-grant-settlement-is-a-compliance-reminder-for-pv-teams</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>Cyion&#x27;s $528,336 grant settlement is a compliance reminder for PV teams</news:title></news:news></url><url><loc>https://vigi-eye.com/analysis/2026-11-17-xortx-completes-gout-trial-supply-health-canada-and-fda-filings-are-next</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>XORTX completes gout trial supply; Health Canada and FDA filings are next</news:title></news:news></url><url><loc>https://vigi-eye.com/analysis/2026-11-17-ascentage-s-nrdl-win-lisaftoclax-listed-olverembatinib-kept-after-renegotiation</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>Ascentage&#x27;s NRDL win: lisaftoclax listed, olverembatinib kept after renegotiation</news:title></news:news></url><url><loc>https://vigi-eye.com/analysis/2026-11-17-fda-closes-dr-reddy-s-bachupally-fto-3-inspection-as-vai-what-it-means</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>FDA closes Dr. Reddy&#x27;s Bachupally FTO-3 inspection as VAI: what it means</news:title></news:news></url><url><loc>https://vigi-eye.com/analysis/2026-11-17-orphan-status-joins-fast-track-for-noema-s-basimglurant-what-it-does-and-doesn-t</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>Orphan status joins Fast Track for Noema&#x27;s basimglurant: what it does and doesn&#x27;t mean</news:title></news:news></url><url><loc>https://vigi-eye.com/analysis/2026-11-17-rasonque-authorised-in-the-eu-what-pv-teams-can-and-cannot-yet-say-about-daraxon</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>Rasonque authorised in the EU: what PV teams can and cannot yet say about daraxonrasib</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/e68a63819586c74d6356</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19</news:publication_date><news:title>Scancell&#x27;s melanoma DNA vaccine iSCIB1+ gets FDA RMAT designation ahead of Phase 3</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/a0499d6290a40af8</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19</news:publication_date><news:title>EEA Joint Committee amends Annex I on veterinary and phytosanitary matters</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/18980445e4c71789</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19</news:publication_date><news:title>EEA Joint Committee amends Annex I on veterinary and phytosanitary matters in Decision 190/2026</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/2a721e4af81e8320</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19</news:publication_date><news:title>EEA Joint Committee amends veterinary, phytosanitary and technical regulation annexes in Decision No 194/2026</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/7684a6aaf9abf708</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19</news:publication_date><news:title>EEA Joint Committee amends Annex I on veterinary and phytosanitary matters in Decision 191/2026</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/f7ade181bc7b7354</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19</news:publication_date><news:title>EEA Joint Committee extends three EU feed additive rules to Iceland and Norway</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/233edaf1882b35f9</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19</news:publication_date><news:title>EEA Joint Committee adds six EU feed additive acts to Annex I of EEA Agreement</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/b86e4779bca9f9b7</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>FDA early alert: Tablo power cord connections may overheat, Outset Medical updates instructions</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/a2f3aa30bcd00db8</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>BfArM publishes urgent field safety notice for Bentley InnoMed&#x27;s BeFlow Iliac Covered Stent System</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/n/32cdc83302adad7f79e1</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>Health Canada lists Class II recall of Stryker&#x27;s Blueprint shoulder-planning software over two bugs</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/n/b900a624e3076f45636c</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>Teleflex recalls PICC kits and spring-wire guides over coating detachment risk, Health Canada reports</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/n/74bd54bab7de0fe71713</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>Health Canada flags Beckman Coulter DxC 500i software fault that may distort chemistry results</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/n/4e319938ba4a21570f4e</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>Health Canada: Raz Design recalls shower commode chairs over seats that can break</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/af2c9505abc693eefd93</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>CMS moves Alimetry&#x27;s Gastric Alimetry test to higher Medicare outpatient payment tier for 2027</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/ffc55cda3c41e622ce7d</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>Prenetics widens H2 EBITDA loss guidance to $30-35M as IM8 spending rises</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/7d6f7a562fb982938949</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>Summit starts Phase III HARMONi-10 of ivonescimab against durvalumab in Stage III NSCLC</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/befca81e4b86e05ab8c1</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>Quantum-Si detects all 20 amino acids at single-molecule level on Proteus platform</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/18ca2a6aa95bc4e95091</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>NeOnc deck reports Phase 2a intranasal NEO100 results in recurrent IDH1-mutant glioma</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/27671f4a22ae3d7d59ee</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>NeOnc to meet FDA in January 2027 on NEO100 accelerated approval path</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/61108086bf67f9b210e9</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>Lantern Pharma opens first TNBC trial site, starts HARMONIC Part 2 in Taiwan; CEO resigns</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/aa103861558c86af26d7</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>newcleo reports Q3 revenue of about €10M and €233.4M cash as PRECURSOR e-core completed</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/659d7e72ea0b3db3093e</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>Optimi Health seeks to make psilocybin depression study randomised Phase 2b; MDMA Phase 3 planned</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/72541949943ca65c87ca</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>Can-Fite completes dosing in interim cohort of Phase III piclidenoson psoriasis trial</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/n/979842eafc32f7134ad5</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>EMA publishes list of Union reference dates and PSUR submission frequencies</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/9edf275bbd603bb4</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>FDA approves Infilbray, first treatment for neurological symptoms of Type 3 Gaucher disease</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/994257e029383655</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>BfArM lists Siemens field safety notice for Dimension Urine Barbiturate Screen assay</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/18fa57f1289d3e63</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>BfArM publishes Medtronic MiniMed urgent field safety notice for MiniMed Go app</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/11d40ae739432f20</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>BfArM posts Merit Medical field safety notice for Philips BridgeT Balloon Prep Kit</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/2efbe70934c21a68</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>BfArM posts Urgent Field Safety Notice for Biomet UK&#x27;s Avantage Cup Gripper</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/d89e90d6d31312e6</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>BfArM publishes InterSystems field safety notice for TrakCare France software</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/5eb843f3ce8c9fac</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>INFARMED lifts suspension of Limeciclina Atral 408 mg capsules after bioequivalence shown</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/1aba554d584f688c</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>ANSM orders Unither&#x27;s Coutances site to fix aseptic and deviation failings within set deadlines</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/c4292c1a9ea49aef</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>ANSM amends French generic groups directory in decision dated 12 November 2026</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/785a65c35b71e5c6</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>Missouri doctor and spouse plead guilty to illegal prescribing and healthcare fraud conspiracies</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/488c5c3cf8a89bcc</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>InnovAge to pay $36m to settle False Claims Act allegations over PACE care failures</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/150df41390e40d20</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>Mississippi businessman jailed for 10 years over $19M Medicare DME fraud</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/49e7108d92d5fd4d</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>Luxembourg launches national campaign on appropriate antibiotic use for European Antibiotic Awareness Day</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/a1f70801876b2793</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>ANSM bans direct furosemide sales to pharmacies and allows compounded capsules amid shortage</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/03b0f8717297aff2</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>Denmark flags Aimovig 140 mg supply problems linked to manufacturing issues</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/613600e0391413ac</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>Denmark flags supply problems with Baxter&#x27;s Sendoxan 50 mg cyclophosphamide tablets until early December</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/75cea3d503f4de8c</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>Michigan pharmacy owner jailed for 82 months over $5.6M fraud and oxycodone diversion</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/8511de07b6a436c6</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>ANSM bans direct lab sales of furosemide to pharmacies as shortage seen lasting into 2027</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/dc8571db1dc3a215</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>Commission publishes minutes of SCHEER working group meeting on brain stimulators</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/3b6077e8e28c953c</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>EU Health Security Committee urges stronger action on carbapenem-resistant bacteria as infections rise</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/42fdfccad122cc5b</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>AIFA starts rolling review of daraxonrasib after positive CHMP opinion in pancreatic cancer</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/48b1ee13611dd77e</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>AIFA reminds sponsors how to pay Annual Safety Report evaluation fee</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/2816e5e66a910281</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>Portugal&#x27;s antibiotic use stays below EU average, but broad-spectrum prescribing remains a concern</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/fdd22cb435433823</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>Paul-Ehrlich-Institut Highlights Vaccines and Antibodies in Fight Against Antimicrobial Resistance</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/bee6e069f5bda240</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>MHRA develops AdvanceGxP service to bring GxP advice into early innovation</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/86ba208bca109705</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>MHRA announces AdvanceGxP service for earlier support on advanced manufacturing technologies</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/23144792c61a8e88</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>MHRA updates London AI regulatory sandbox call with next-stage application details</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/4c022c8dd289c926</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>Slovenia asks wholesalers to import estradiol 50 microgram patches amid supply disruption</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/627171d8281b8379</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>SÚKL says no Comirnaty batch inspected or vaccine withdrawn after 2020–2026 pharmacovigilance signals</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/2f78271f1980fd42</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>SÚKL explains why Czech pharmacies may split repeat-prescription dispensing across days</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/n/16882a5c9db976095099</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>MHRA updates London Region I sandbox call with next-stage application details</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/a5ac5190ca80fe656df2</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>Iridex cuts 2026 revenue guidance to $46-48M after 19% third-quarter sales drop</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/8ec055ab42a83d54ce95</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>Inhibrx reports 62.7% response rate for ozekibart combination in relapsed Ewing sarcoma</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/72a975f5aef6d839c386</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>Interpace Biosciences Q3 revenue rises 18% to $10.4M on thyroid testing growth</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/n/ca88de81079ce5c24966</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>Health Canada flags foreign matter in four lots of Pendopharm&#x27;s PegLyte Powder</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/399d7c55a6c957a09334</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>Viatris completes $36.50-a-share cash acquisition of Pacira BioSciences after tender offer</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/444f5c177ece5ac1881a</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>Adagene and City of Hope launch Phase 1 trial of ivonescimab plus muzastotug in colorectal cancer</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/3563ae5ee73281185684</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>MAIA reports 88% disease control for ateganosine-cemiplimab in third-line NSCLC</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/e7d4b363b1d0dbfa7588</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>Allarity extends Phase 2 stenoparib ovarian cancer trial to platinum-refractory and non-RECIST patients</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/e14dbbc81716ffffc9b6</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>OXB confirms manufacturing deal with Aura Biosciences for bel-sar Phase 3 and commercial supply</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/a209e23e22ad27b16a5f</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>Zentek reports C$15.2M six-month profit on impairment reversal; cash rises to C$13.6M</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/df13d1a24e5ca4d50705</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>UL Solutions to acquire supply chain software firm Worldly in roughly $350M deal</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/3b6c2fb8303f5bc6cb8a</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>Vivos Therapeutics regains Nasdaq equity compliance as Q3 revenue rises 24% sequentially</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/9413b4faeb38ab58d2e1</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>NeOnc says NEO100 met Phase 2a endpoint in recurrent IDH1-mutant glioma, but criteria diverge</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/08d4587df06c2869c73c</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>Mesoblast reports US$115M first full-year Ryoncil sales and advances four late-stage programmes</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/1fb366ae65a9f052eb3f</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>FDA approves Novartis&#x27; Cosentyx 150 mg for polymyalgia rheumatica</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/d1ef32c47d53b651</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>Diagnostica Stago recalls lot of STHEMO DDi M, Dutch inspectorate notice shows</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/ed248f9155b70d9b</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>CMS publishes Performance Year 2025 results for Medicare Shared Savings Program ACOs</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/446eb2a732e63965</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>Medicare Shared Savings Program posts $2.5bn net savings in 2025, a ninth straight year</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/f038159aee765250</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>CMS publishes 2027 Medicare Part A and B premiums, deductibles and Part D income-related adjustments</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/ee96ce9b669fea39</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>BfArM lists Arthrex field safety notice for NanoNeedle Scope</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/8a0870abea9641df</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>BfArM publishes Urovision urgent field safety notice for VISIO-WEB WEBSINGER catheter</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/c402f431add9e9ac</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>BfArM publishes Intelerad field safety notice for InteleShare imaging software</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/2c939cbd389de27e</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>BfArM lists urgent field safety notice for Hitachi cobas c 303 analytical unit</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/bfa8bbd8fa4b04bc</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>FDA launches Global Reliance Disclosure Program to share approval packages for foreign regulators&#x27; use</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/2335622373282e83</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>FDA approves Lembaz, first drug shown to extend survival in infantile-onset Niemann-Pick type C</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/1849bb4ae07d92f7</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>Infarmed allows English-labelled Teva UK dapagliflozin to ease Dalzior 10 mg supply shortage in Portugal</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/2d57947efffd2dbd</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>MHRA lists eight device Field Safety Notices in weekly update for 9–13 November</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/3370c1a3cd3f56de</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>AIFA publishes sunset clause pre-notice for medicines facing lapse in early 2027</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/e32b7967f310e718</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>Estonia&#x27;s medicines agency publishes 2026 statistical yearbook covering 2021–2025 market and use trends</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/efb2c1206e9df0d5</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>AIFA issues sunset clause pre-notice for products at risk of lapsing in early 2027</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/21ae3230ee8f2d62</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>EMA group publishes amended EU influenza vaccine composition recommendations for 2026/2027 season</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/544ec4dd4d5ed12f</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>EMA extends 2026/2027 flu vaccine composition advice to mRNA influenza vaccines</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/534c2b9e68b8af9a</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>Fimea asks medical device operators to check register data by 31 December 2026</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/0fea7ce39f91c8b9</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>AEMPS veterinary committees note 21 pharmacovigilance-driven authorisation changes and recall follow-up problems</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/8872ab28e3df0141</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>FDA classes Cardinal Health Presource kit correction as Class I over recalled BD Alaris infusion sets</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/49215df013c4d271</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>60 European hospitals join EU-JAMRAI 2 antibiotic awareness campaign for AMR Week</news:title></news:news></url></urlset>